Drug Trial Radar · NCT03659916
Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
Sep 28, 2018
Primary completion
Feb 15, 2024
Study completion Dec 2, 2025
Sponsor
- Lead sponsor
- Albireo, an Ipsen CompanyIndustry
- Sponsor type
- Industry
- First posted
- Sep 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 months, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label extension study to evaluate long-term safety and persistence of effect of A4250 in children with progressive familial intrahepatic cholestasis (PFIC).
Conditions
- Progressive Familial Intrahepatic Cholestasis
Interventions
A4250 (odevixibat)Drug
A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Positive Pruritus Assessments at the Participant Level Over 72-Week Using the Albireo Observer-Reported Outcome (ObsRo) Instrument (Combined AM and PM Scores)Time frame: Week 72
Locations
41 sites in 15 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California
Children's Hospital Colorado
Denver, Colorado
Emory University School of Medicine
Atlanta, Georgia
Riley Hospital for Children - Riley Children's Specialists
Indianapolis, Indiana
Johns Hopkins School of Medicine
Baltimore, Maryland
Washington University School of Medicine
St Louis, Missouri
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University Medical Center - Presbyterian Hospital Building
New York, New York
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Baylor College of Medicine - Texas Children's Liver Center
Houston, Texas
The Royal Children's Hospital
Melbourne, Australia
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert, Belgium
The Hospital for Sick Children
Toronto, Canada
University and Pediatric Hospital of Lyon
Bron, France
Universite Paris SUD - Hpitaux Universitaires Paris-Sud - Hopital Bicetre
Le Kremlin-Bicêtre, France
Hospital De La Timone
Marseille, France
Hospital Necker-Enfants Maladies
Paris, France
Medizinische Hochschule Hannover
Hanover, Germany
Kinderklinik Tubingen, Universitatsklinikum Tubingen
Tübingen, Germany
Univesitatsklinikum Tubingen Klinik fur Kinder und Jugendmedizin
Tübingen, Germany
Shaare-Zedek Mc
Jerusalem, Israel
Schneider Children's Medical Center Of Israel
Petah Tikva, Israel
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo, Italy
University Hospital Of Padova
Padova, Italy
Ospedale Regina Margherita
Torino, Italy
University Medical Center Groningen
Groningen, Netherlands
Universitair Medisch Centrum (UMC) Utrecht
Utrecht, Netherlands
Instytut Pomnik - Centrum Zarowia Dziecka
Warsaw, Poland
King Faisal Specialist Hospital & Research Centre
Riyadh, Saudi Arabia
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario La Paz
Madrid, Spain
Astrid Lindgren Children's Hospital, Karolinska University Hospital
Solna, Sweden
Gazi University
Ankara, Turkey (Türkiye)
Hacettepe University Faculty of Medicine
Ankara, Turkey (Türkiye)
Akdeniz University
Antalya, Turkey (Türkiye)
Istanbul University Medical Faculty
Istanbul, Turkey (Türkiye)
Inonu University Medical Faculty
Malatya, Turkey (Türkiye)
Birmingham Women's and Children's NHS Foundation Trust
Birmingham, United Kingdom
Leeds General Infirmary
Leeds, United Kingdom
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.